LPP and cranioectodermal dysplasia: Galatola M, et al. have explored the possibility of the development of a non-invasive biomarker obtainable from peripheral circulation by carrying out gene expression analysis using peripheral blood mono-nuclear cells (PBMCs) and they defined a 4 gene PBMC signature including NFKB, IL-21, LPP, and RGS1 for discriminating patients with CeD from non-CeD individuals [88].